Emicizumab biosimilar(Hangzhou Jiuyuan Gene Biomedical Co Ltd)

艾美赛珠单抗生物类似药（杭州九源基因生物医药股份有限公司）

Report date: 2025/11/05 10:34:47

Base Information

Drug NameEmicizumab biosimilar(Hangzhou Jiuyuan Gene Biomedical Co Ltd)
Drug Alias NameJY56JY-56
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCoagulation factor IX modulatorsCoagulation factor X modulators
TargetsCoagulation factor IXCoagulation factor X
Therapy Area/IndicationsHemophilia A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHangzhou Jiuyuan Gene Biomedical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Jiuyuan Gene Biomedical Co Ltd
Inactive CompaniesN/A
Active IndicationsHemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A